Evotec

Large Pharma Partnerships And AI Platforms Will Open New Markets

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

30 Apr 25

Updated

03 Dec 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-36.6%

-3.4%

-36.6%

-3.4%

You can edit this narrative until Dec 4 7:05 PM. Then, changes will post as Updates.

Author's Valuation

€8.4634.8% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on 03 Dec 25

Fair value Decreased 11%

EVT: Share Buybacks And Milestone Payment Will Support Future Upside

Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.

Shared on 21 Aug 25

Fair value Decreased 14%

The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.

AnalystConsensusTarget Fair Value

€8.46

34.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.33%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.57%

Calculation

€76.50m

Earnings '28

23.82x

PE Ratio '28

€1.82b

Market Cap '28

€1.82b

Market Cap '28

178.53m

No. shares '28

€10.21

Share Price '28

€10.21 Share Price '28

Discounted to 2025 @ 6.56% p.a.

€8.44

Fair Value '25